Frontlight ResearchEarly access
Taking people in SpainPhase 2
Rimonabant for thinking and memory problems after COVID-19
Tests rimonabant against placebo for cognitive problems in adults with post-COVID-19 syndrome.
Key facts
- Who runs it
- Sinfatin S.L.
- Where
- Albacete, Madrid, San Sebastián, and Toledo, SpainSee the 4 sites
- Trial code
- Registry title
- Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 26 Oct 2026
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional
- Record updated
- 28 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with post-COVID-19 syndrome (long COVID) who have ongoing memory or concentration problems. It compares rimonabant with placebo.
- Age
- 18 to 75 years (both included)
- Sex
- Women and men can join.
- Disease stage
- Active post-COVID-19 syndrome (long COVID), with COVID-19 at least 3 months before joining, ongoing memory or concentration problems, and signs of cognitive impairment in study assessments.
- Earlier treatment
- Must not have taken part in another clinical trial within the last month. Must not take medicines that may interact with the study treatment or that may affect memory or concentration.
- Biomarker or test result
- Brain Fog Scale (BFS) score of 47 or higher.
Main reasons for not taking part
- Active or recent COVID-19 infection
- Severe lung, heart, liver, kidney or bone disease
- Body mass index (BMI) greater than 40 kg/m²
- Major depressive disorder, severe anxiety disorder or other severe mental health condition, or high risk of suicide
- Pregnant or breastfeeding, or able to become pregnant or father a child without effective contraception
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Be aged between 18 and 75 years (both inclusive)
- Have had COVID-19 at least 3 months before joining the study
- Have been diagnosed with active PCS (Long COVID)
- Have ongoing problems with memory or concentration due to long-COVID syndrome
- Show signs of cognitive impairment in study assessments
- Be willing to complete study assessments
- Be able to understand and speak Spanish
- Provide written consent to participate
- Indication of brain fog symptoms: BFS (Brain Fog Scale) ≥ 47
Who cannot take part
- Use substances or medications that may affect memory or concentration
- Have severe mental health conditions (as per clinical records): major depressive disorder; severe anxiety disorder; bipolar disorder; schizophrenia or schizoaffective disorder; psychotic disorder; previous suicide attempt; any psychiatric disorder requiring psychiatric hospitalization; any other severe psychiatric condition that, in the investigator's opinion, may compromise participant safety or interfere with study
- Have an active or recent COVID-19 infection
- Have other medical conditions that could explain their symptoms
- Have severe lung, heart, liver, kidney, or bone disease
- Major depressive disorder or severe anxiety disorder, according to DSM-5-TR criteria: Scores ≥ 20 on the BDI-II or ≥ 11 on the HADS at screening, followed by the confirmation of the diagnosis by a health professional (psychologist or psychiatrist)
- Have a known allergy to rimonabant
- Have neurological conditions that may affect memory or concentration
- Have a body mass index (BMI) greater than 40 kg/m²
- Are unable to walk or attend study visits
- Are taking medicines that may interact with the study treatment
- Have taken part in another clinical trial within the last month
- Are pregnant or breastfeeding
- Are able to become pregnant or father a child and are not using effective contraception
- Have a high risk of suicide
Where in Spain
- Hospital General Universitario de AlbaceteAlbacete, SpainTaking people
- Hospital Clínico San CarlosMadrid, SpainTaking people
- ATHENEA NeuroclinicsSan Sebastián, SpainTaking people
- Hospital Nacional De ParaplejicosToledo, SpainTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of rimonabant in improving cognitive impairment in patients with post-COVID-19 syndrome compared to placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)
- Plain-language title
- Rimonabant for thinking and memory problems after COVID-19Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 September 2026